<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04757259</url>
  </required_header>
  <id_info>
    <org_study_id>20-605</org_study_id>
    <nct_id>NCT04757259</nct_id>
  </id_info>
  <brief_title>Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From Cerdulatinib</brief_title>
  <official_title>An Expanded Access Protocol for Patients Who Completed Study 13-601 and Continue to Clinically Benefit From Cerdulatinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      This expanded access program will provide continued access to cerdulatinib to eligible&#xD;
      participants who experienced clinical benefit from cerdulatinib in Study 13-601 (NCT01994382)&#xD;
      and who otherwise meet the eligibility criteria.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Relapsed/Refractory Chronic Lymphocytic Leukemia</condition>
  <condition>Non-hodgkin's Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cerdulatinib</intervention_name>
    <description>Participants will receive oral cerdulatinib at the starting dose he or she was receiving at completion of Study 13-601 (30, 25, 20, or 15 milligrams [mg] twice daily [BID]).</description>
    <other_name>PRT062070</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant has completed Portola Study 13-601 and wishes to continue treatment with&#xD;
             cerdulatinib.&#xD;
&#xD;
          -  In the opinion of the Investigator, the potential benefit to the participant of&#xD;
             continuing to receive cerdulatinib outweighs the risks.&#xD;
&#xD;
          -  Female participants of childbearing potential and male participants must agree to&#xD;
             continue to abstain from sexual intercourse or to remain on an effective method of&#xD;
             contraception during treatment and for 90 days following the last dose of protocol&#xD;
             therapy (examples of effective methods of contraception include oral contraceptives or&#xD;
             double barrier methods, such as condom plus spermicide or condom plus diaphragm).&#xD;
&#xD;
          -  Participant must be willing to give written informed consent and be able to adhere to&#xD;
             dose and visit schedules.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant requires chronic treatment with a strong CYP3A4 inhibitor or inducer.&#xD;
&#xD;
          -  Participant has a known hypersensitivity to any of the components of cerdulatinib.&#xD;
&#xD;
          -  Participant is female and is breast-feeding, pregnant, or intends to become pregnant.&#xD;
&#xD;
          -  Participant is participating in any therapeutic clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Alexion Pharmaceuticals, Inc.</last_name>
    <phone>855-752-2356</phone>
    <email>20-605.eap@alexion.com</email>
  </overall_contact>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 10, 2021</study_first_submitted>
  <study_first_submitted_qc>February 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2021</study_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

